BioPharm International

BioPharm International, May 2024
Volume: 37
Issue: 5

Partnerships for Outsourcing, May 2024 eBook
Volume: 2024 eBook
Issue: 2

BioPharm International, April 2024
Volume: 37
Issue: 4

BioPharm International, March 2024
Volume: 37
Issue: 3

Quality and Regulatory Sourcebook, March 2024 eBook
Volume: 2024 eBook
Issue: 1

BioPharm International, February 2024
Volume: 37
Issue: 2

BioPharm International, January 2024
Volume: 37
Issue: 1

BioPharm International, December 2023
Volume: 36
Issue: 12

Manufacturing and Facilities, November 2023 eBook
Volume: 2023 eBook
Issue: 4

BioPharm International, November 2023
Volume: 36
Issue: 11

BioPharm International, October 2023
Volume: 36
Issue: 10

BioPharm International, September 2023
Volume: 36
Issue: 9

Emerging Therapies, September 2023 eBook
Volume: 2023 eBook
Issue: 3

BioPharm International, August 2023
Volume: 36
Issue: 8

BioPharm International, July 2023
Volume: 36
Issue: 7

BioPharm International, June 2023
Volume: 36
Issue: 06

Partnerships for Outsourcing, May 2023 eBook
Volume: 2023 eBook
Issue: 2

BioPharm International, May 2023
Volume: 36
Issue: 05

BioPharm International, April 2023
Volume: 36
Issue: 04

BioPharm International Quality and Regulatory Sourcebook 2023
Volume: 2023 eBook
Issue: 1

BioPharm International, March 2023
Volume: 36
Issue: 03

BioPharm International, February 2023
Volume: 36
Issue: 02

BioPharm International, January 2023
Volume: 36
Issue: 01

BioPharm International, December 2022
Volume: 35
Issue: 12

BioPharm International, Manufacturing and Facilities November 2022
Volume: 2022 eBook
Issue: 4

BioPharm International, November 2022
Volume: 35
Issue: 11

BioPharm International, October 2022
Volume: 35
Issue: 10

BioPharm International, September 2022 Issue
Volume: 35
Issue: 9

BioPharm International, Emerging Therapies September 2022
Volume: 2022 eBook
Issue: 3

BioPharm International, August 2022 Issue
Volume: 35
Issue: 8
Advertisement
Advertisement
Trending on BioPharm International
1
Biocon’s Pebrilzo Becomes First Breast Cancer Treatment Biosimilar Approved Under EMA’s Tailored Clinical Approach
2
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
3
AbbVie and DISCO Partner on AND-Gated Bispecifics Designed to Recognize Tumor-Selective Protein Pairs
4
FDA Approves First RNAi Therapeutic for Generalized Myasthenia Gravis
5

